Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study.

Authors: Joshua J. Meeks, Roger Li, Ashish M. Kamat, Girish S. Kulkarni, Noah M. Hahn, Ekta Kapadia, Qing Zhao, Hema Kishore Dave, Max Kates

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4627

Source: Full article

---

Abstract

TPS4627